Introduction
============

Osteoporosis (OP) can be diagnosed indirectly via non-invasive measurements of bone mineral density (BMD) ([@b1-mmr-19-06-4603]). In recent years, men have been shown to be affected by this 'silent epidemic'. The prevalence of OP was found to be between 6 and 22% in men ([@b2-mmr-19-06-4603]). The lifetime risk of osteoporotic fractures in men is approximately one-third of that in women ([@b3-mmr-19-06-4603]). OP-related fractures are associated with higher mortality rates in men than in women ([@b4-mmr-19-06-4603]). Thus, male OP should draw more attention from clinicians worldwide.

The relationship between hypercholesterolemia and osteoporosis in men has been preliminarily discovered ([@b5-mmr-19-06-4603]). To the best of our knowledge, the widespread and profound effects of hypercholesterolaemia on male bone and their underlying mechanisms have seldom been reported thus far. As the prevalence of hypercholesterolaemia in male adults is increasing, and is even higher than that in females ([@b6-mmr-19-06-4603]), the effects of hypercholesterolaemia on male bone should attract sufficient attention. Therefore, we aimed to investigate the effects of hypercholesterolaemia on male bone and the underlying mechanisms.

Materials and methods
=====================

### Human subjects and design

Between July 2015 and October 2015, 216 men (aged ≥18 years) were recruited by the Jinan Health Organization (Jinan, China). All subjects completed a self-reported questionnaire including items pertaining to their demographic characteristics, lifestyle habits, dietary habits, medical histories and current medications. Height and body weight were measured to calculate body mass index (BMI) using the following formula: BMI=body weight (kg)/height (m^2^). Fasting blood samples were drawn for clinical laboratory tests.

The exclusion criteria included participants with chronic diseases, hepatic, renal, thyroid, other endocrine diseases, diabetes and hypertriglyceridemia and participants taking medications such as glucocorticoids, testosterone, thyroid hormone, bisphosphonates, calcitonin, calcium and active vitamin D analogues. Overall, 216 men were enrolled in the present study, which was approved by the Ethics Committee of Provincial Hospital Affiliated with Shandong University (Jinan, China) and all participants provided written informed consent before participating in the study.

According to the criteria outlined in China\'s Adult Dyslipidemia Prevention Guide (2016 version) ([@b7-mmr-19-06-4603]), the 216 men enrolled in the present study were divided into a hypercholesterolaemia group (total cholesterol ≥5.20 mmol/l, n=102) and a control group (total cholesterol \<5.20 mmol/l, n=114).

### Clinical laboratory tests and BMD measurements

Serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and fasting plasma glucose (FPG) levels were measured by the Beckman Chemistry Analyzer AU5800 System 195 (Beckman Coulter, Inc., Tokyo, Japan) and beta collagen cross-linking (beta-CTX), type I anterior collagen amino terminal peptide (PINP), testosterone (To), free thyroxine (FT4), thyroid stimulating hormone (TSH) and 25-hydroxyvitamin D \[25(OH)D\] concentrations were determined by an electrochemiluminescence immunoassay (Cobas 8000 analyser; Roche Diagnostics, Basel, Switzerland) at the Clinical Laboratory of Shandong Provincial Hospital. BMD was measured in the low-median region of the left forearm by a trained technologist using a dual-energy X-ray absorptiometry (DXA) fan beam bone densitometer (EXA-3000; OsteoSys, Co., Ltd., Seoul, Korea).

### Animal experimental design

The animal experimental protocol was approved by the Animal Ethics Committee of Shandong Provincial Hospital. Two animal models were used in this study. For the first model, 24 6-week-old male Sprague-Dawley rats weighing approximately 200 g were obtained from Vital River Laboratory Animal Technology Co, Ltd. (Beijing, China). Following being acclimated to their housing environments for 1 week, the rats received one of two diets, a normal control diet (NCD, 100% standard rodent chow) or a high cholesterol diet (HCD, 2% cholesterol + 98% standard rodent chow), and were randomly assigned into three groups: An NCD group (36 weeks), an HCD group (36 weeks), or an HCD+NCD group (24 weeks HCD+12 weeks NCD). Rats of the second model included male wild-type (ApoE^+/+^) rats and male ApoE-knockout (KO) (ApoE^−/−^) rats, which were obtained by breeding heterozygous (ApoE^+/−^) rats purchased from Beijing Biocytogen Co., Ltd. (Beijing, China) and were fed an NCD for 20 weeks. All animals were maintained in temperature-controlled rooms (22--25°C) under 12-h light/dark cycles and allowed free access to food and water. All rats were sacrificed by exsanguination following anesthesia with subcutaneous injection of 30 mg/kg pentobarbital sodium at the end of the feeding period after being fasted for 8 h. Body weights were obtained, and fasting blood samples were withdrawn. The left femurs were collected and cleaned of soft tissue before being packed in gauze soaked with a NaCl solution (9 g/l) and stored at −30°C.

### Serum parameter analysis

Serum lipid profiles were measured by an Olympus AU5400 automatic biochemical analyser (Olympus Corp., Mishama, Japan). Serum tartrate-resistant acid phosphatase (TRAP), beta-CTX, PINP, bone alkaline phosphatase (ALPL) and bone glaprotein (BGP) were measured with ELISA kits (Uscn Life Science, Inc., Wuhan, China).

### Micro-CT (mCT) measurements

The trabecular and cortical microarchitectures of the left femurs were analysed using mCT (SkyScan 1176; Bruker-microCT, Kontich, Belgium). The slice thickness was 17.93 µm, and the voxel resolution was 22 µm^3^. Quantitative analyses of the morphometric parameters were conducted using the appropriate software package, and 3D images of the distal femur and femoral diaphysis were reconstructed for visualization. All analyses were conducted by a trained professional in a blinded manner who was unaware of the treatments to which the specimens had been subjected.

### Biomechanical property measurement

We assessed the mechanical properties of the femoral diaphysis as previously reported ([@b8-mmr-19-06-4603]) using an ElectroForce 3230 Bose System (Bose, Minnetonka, MN, USA). Based on these parameters reported by the instrument, we analysed the mechanical properties of the femoral diaphysis.

### Primary culture of osteoblasts

Primary osteoblasts obtained from new-born rats were cultured as described in a previous study ([@b9-mmr-19-06-4603]). The cells were cultured in 6-well plates at a density of 1×10^5^ cells/well in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% (v/v) fetal bovine serum (FBS; Biochrom GmbH, Berlin, Germany), 100 U/ml penicillin-streptomycin solution (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 2 mM L-glutamine (Sigma-Aldrich; Merck KGaA) at 37°C in a humidified 5% CO~2~ atmosphere. The medium was refreshed every 48 h. Haematoxylin and eosin (H&E) staining was used to identify the typical morphological characteristics of the osteoblasts. Alkaline phosphatase (ALP) (Genmed, Shanghai, China) staining, Alizarin red (Beijing Solarbio Science & Technology Co. Ltd. (Beijing, China) staining and Von Kossa (Genmed) staining were performed for osteoblast phenotypic and functional identification. After 3 days of incubation at 37°C in a humidified 5% CO~2~ atmosphere, the primary osteoblasts were starved of serum for 2 h and then treated with cholesterols (Sigma-Aldrich; Merck KGaA; 0, 10 and 20 µg/ml) for 12, 24 and 48 h. We subsequently analysed osteoblast function by measuring gene expression.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted using TRIzol (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer\'s instructions. cDNA was synthesized from 500 ng of total RNA using ReverTra Ace reverse transcriptase (Takara Biotechnology Co., Ltd.) and oligo dT primers (Takara Biotechnology Co., Ltd.). The following PCR primers were used in the study: ALPL: Forward (F), 5′-CATCGCCTATCAGCTAATGCACA-3′ and reverse (R), 5′-ATGAGGTCCAGGCCATCCAG-3′; collagen I: F, 5′-GACATGTTCAGCTTTGTGGACCTC-3′ and R, 5′-AGGGACCCTTAGGCCATTGTGTA-3′; BGP: F, 5′-GGACCCTCTCTCTGCTCACTCT-3′ and R, 5′-CTTACTGCCCTCTGCTTGG-3′; β-actin: F, 5′-ACCCAGATCATGTTTGAGAC-3′ and R, 5′-GTCAGGATCTTCATGAGGTAGT-3′.

### Extracellular protein ELISA

Secreted BGP and ALPL levels were measured with ELISA kits (Uscn Life Science, Inc.) according to the manufacturers\' protocols. The protein concentration of the cell homogenate was determined using a BCA assay (Shen Neng Bo Cai Corp., Shanghai, China). The levels of BGP and ALPL in the media were normalized to the total cellular protein content.

### Statistical analysis

Statistical analyses were performed using SPSS 22 (IBM Corp., Armonk, NY, USA). All data are expressed as the mean ± standard deviation for continuous variables. Unpaired Student\'s t-test or one-way analysis of variance (ANOVA) and LDS, S-N-K, Duncan and Dunnet post hoc tests were used to compare BMD, beta-CT X and PINP levels between hypercholesterolaemia and controls and all animal and cell measurement data. Multivariate linear regression analysis was used to evaluate the correlations between clinical parameters and serum BMD and beta-CTX and PINP levels. P-values \<0.05 were considered to indicate a statistically significant result.

Results
=======

### Correlation between serum cholesterol and BMD, beta-CTX and PINP

[Table I](#tI-mmr-19-06-4603){ref-type="table"} presents the characteristics of both groups. BMD was significantly lower in men with hypercholesterolaemia than in control subjects (P\<0.001), and both beta-CTX and PINP levels were increased in the hypercholesterolaemia group compared with those in the controls (P\<0.05). Moreover, serum TC, LDL-C and HDL-C levels were significantly higher among men with hypercholesterolaemia (P\<0.001). There were no significant differences in the age, BMI or FPG, HbAc1, To, FT4, TSH, 25(OH)D and TG levels between the two groups.

To further study the effects of cholesterol on BMD and beta-CTX and PINP levels, we performed multiple linear regression analysis ([Table II](#tII-mmr-19-06-4603){ref-type="table"}) in which beta-CTX and PINP served as dependent variables and other factors served as independent variables. As shown in [Table II](#tII-mmr-19-06-4603){ref-type="table"}, TC was a significant independent predictor of BMD, beta-CTX and PINP and was negatively correlated with BMD and positively correlated with beta-CTX and PINP. LDL-C was positively correlated with beta-CTX levels but was not significantly correlated with BMD or PINP levels.

### Effects of HCD and HCD withdrawal on bone in male rats

Serum cholesterol levels were higher in HCD rats than levels in the controls (P\<0.01), inducing exogenous hypercholesterolaemia in these rats, and these levels were diminished in the HCD+NCD rats compared with those in the HCD rats (P\<0.01), and there was no significant difference in TG or body weight among the three groups ([Fig. 1A](#f1-mmr-19-06-4603){ref-type="fig"}).

The bone mCT measurements are shown in [Table III](#tIII-mmr-19-06-4603){ref-type="table"}. HCD administration decreased trabecular and cortical vBMD ([Fig. 1D](#f1-mmr-19-06-4603){ref-type="fig"}) and caused microstructural damage ([Fig. 1B and C](#f1-mmr-19-06-4603){ref-type="fig"} and [Table III](#tIII-mmr-19-06-4603){ref-type="table"}); [Fig. 1B](#f1-mmr-19-06-4603){ref-type="fig"} is two-dimensional and cross-sectional scanning structure, and [Fig. 1C](#f1-mmr-19-06-4603){ref-type="fig"} is three-dimensional structure synthesized by computer analysis, showing the microstructure of bone in a more detailed manner. vBMD was higher in the HCD+NCD rats than that in the HCD male rats ([Fig. 1D](#f1-mmr-19-06-4603){ref-type="fig"}). The levels of mCT 3D microstructural damage were ameliorated in HCD withdrawal rats compared with those in the HCD rats ([Table III](#tIII-mmr-19-06-4603){ref-type="table"}). These results suggest that HCD passively affected both trabecular and cortical bone, especially trabecular bone and that dietary modification can weaken these effects.

The levels of bone biomechanical parameters were increased significantly or tended to increase in HCD withdrawal rats compared with those in HCD rats ([Fig. 1E and F](#f1-mmr-19-06-4603){ref-type="fig"}). These results suggest that HCD caused deteriorations in bone strength and that dietary modification can mitigate these effects.

Our assessment revealed that the levels of serum bone resorption markers (TRAP and CTX--I) were significantly increased in HCD rats compared with those in the controls; however, they decreased after HCD withdrawal ([Fig. 1G](#f1-mmr-19-06-4603){ref-type="fig"}). Therefore, bone formation markers (BGP, ALPL and PINP) were identified ([Fig. 1H](#f1-mmr-19-06-4603){ref-type="fig"}). These results suggest that HCD administration elevated both bone resorption and bone formation, and dietary modification can alleviate these effects.

### ApoE^−/−^ male rat bone loss

Serum cholesterol levels were significantly higher in ApoE^−/−^ male rats than in ApoE^+/+^ rats (P\<0.01), inducing endogenous hypercholesterolaemia. There were no differences in TG levels or body weight between the two groups ([Fig. 2A](#f2-mmr-19-06-4603){ref-type="fig"}).

The levels of bone mCT measurements are shown in [Table III](#tIII-mmr-19-06-4603){ref-type="table"}. ApoE^−/−^ male rats displayed decreased trabecular and cortical vBMD ([Fig. 2D](#f2-mmr-19-06-4603){ref-type="fig"}) and microstructural damage ([Fig. 2B and C](#f2-mmr-19-06-4603){ref-type="fig"}) compared with ApoE^+/+^ rats. These results suggest that ApoE^−/−^ rats experienced significant trabecular and cortical bone loss and damage.

Regarding the biomechanical parameter measurements, the maximum load, maximum fracture load, stiffness and elastic modulus of the femoral diaphysis were apparently lower and energy absorption tended to decrease in ApoE^−/−^ rats compared with those in ApoE^+/+^ rats ([Fig. 2E and F](#f2-mmr-19-06-4603){ref-type="fig"}).

Our assessment revealed that the serum levels of both bone resorption markers (TRAP and CTX--I) and bone formation markers (BGP, ALPL and PINP) were increased in ApoE^−/−^ male rats compared with those in ApoE^+/+^ rats ([Fig. 2G and H](#f2-mmr-19-06-4603){ref-type="fig"}). These results suggest that ApoE^−/−^ rats had elevated bone resorption and bone formation, improving the bone turnover rate.

### Effects of cholesterol on primary osteoblast function

We examined H&E-stained osteoblasts via microscopy ([Fig. 3A-a](#f3-mmr-19-06-4603){ref-type="fig"}). These osteoblasts displayed cytoplasm that appeared violet in response to ALP staining ([Fig. 3A-b](#f3-mmr-19-06-4603){ref-type="fig"}). The cells were subjected to Alizarin red ([Fig. 3A-c](#f3-mmr-19-06-4603){ref-type="fig"}) or Von Kossa staining ([Fig. 3A-d](#f3-mmr-19-06-4603){ref-type="fig"}), revealing the presence of many round or elliptical opaque red or black nodules, which served as additional evidence indicating osteoblast mineralization. All of the above findings suggest that cultured rat calvaria osteoblasts are ideal experimental osteoblast model cells.

With increasing cholesterol doses, BGP, ALPL and collagen I mRNA expression as well as BGP and ALPL protein levels gradually increased compared with those in the control group ([Fig. 3B and D](#f3-mmr-19-06-4603){ref-type="fig"}) after treatment for 24 h, but there were no differences in their levels among the different times tested (12, 24 and 48 h) after 10 µg/ml cholesterol treatment ([Fig. 3C and E](#f3-mmr-19-06-4603){ref-type="fig"}). These results suggested that cholesterol could increase the mRNA and protein expression levels of osteoblast functional genes in a dose-dependent but non-time-dependent manner.

Discussion
==========

Currently, there is a dearth of information in the literature regarding the effects of hypercholesterolaemia on male bone metabolism. However, male osteoporosis (OP) should draw more attention from clinicians worldwide. Elucidating the effects of hypercholesterolaemia on male bone metabolism may aid in the search for answers regarding the relationship between hypercholesterolaemia and male OP and the underlying mechanisms and will further our understanding of the pathomechanisms underlying the relationship between the two diseases to reduce the financial burden imposed by male OP and OP-related hip fractures.

T2 diabetes mellitus (DM), low testosterone (To) and obesity are often associated with elevated plasma cholesterol levels ([@b10-mmr-19-06-4603]--[@b12-mmr-19-06-4603]). Diabetes mellitus (both type 1 and type 2) ([@b13-mmr-19-06-4603]), testosterone deficiency ([@b14-mmr-19-06-4603],[@b15-mmr-19-06-4603]), hyperthyroidism and hypothyroidism ([@b16-mmr-19-06-4603]), body mass index (BMI) ([@b17-mmr-19-06-4603]), and hypertriglyceridemia ([@b18-mmr-19-06-4603],[@b19-mmr-19-06-4603]) reportedly affect bone mineral density (BMD). In this clinical study, we excluded participants with thyroid diseases, diabetes and hypertriglyceridemia according to clinical laboratory test results. There were no differences in BMI or serum fasting plasma glucose (FPG), HbAc1, To, FT4, thyroid stimulating hormone (TSH), 25(OH)D and triglyceride (TG) levels between hypercholesterolaemia and control subjects. Therefore, we investigated the effects of hypercholesterolaemia on male bone, excluding the effects of the abovementioned parameters. Multiple regression analysis suggested that cholesterol was a significant independent predictor of BMD and negatively correlated with BMD. Some clinical studies have demonstrated that cholesterol-lowering statin drugs increase BMD and reduce the risk of OP-associated fractures ([@b20-mmr-19-06-4603],[@b21-mmr-19-06-4603]), supporting our results. We also found that serum cholesterol was a significant independent predictor of beta-CTX and PINP levels and positively correlated with both. Beta-CTX fragments are released into the blood after type I collagen is dissolved by osteoclasts and are recognized as clinical indices of osteoclast activity and bone resorption. PINP directly reflects the rate of osteoblast-mediated collagen synthesis and is recognized as a clinical index of osteoblast activity and bone formation. Thus, we hypothesized that hypercholesterolaemia can promote the development of male OP by promoting both osteoclast-mediated bone resorption and osteoblast-mediated osteogenesis. Our data were inconsistent with those of a previous study ([@b22-mmr-19-06-4603]). Majima *et al* ([@b22-mmr-19-06-4603]) noted that higher TC levels were associated with higher bone turnover marker levels in female patients but not in male patients, perhaps because their study did not exclude other factors, such as male gonadal hypofunction, as stated by the authors in the indicated report. Importantly, the authors did not analyze the association between cholesterol and BMD. We used multiple regression analysis to exclude the effects of FPG, HbAc1, To, FT4, TSH, 25(OH)D and TG on bone, and we believe that our findings are more convincing.

Bone microstructural damage results in low BMD or OP, and reduced bone strength is correlated with a higher risk of bone fracture. Thus, to test our clinical discovery and further explore the effects of hypercholesterolaemia on male bone microstructure and bone strength, we designed two male animal models. High cholesterol diet (HCD)-induced exogenous hypercholesterolaemia and ApoE-knockout (KO)-induced endogenous hypercholesterolaemia were observed in male rats.

HCD administration significantly increased serum cholesterol levels but not serum TG levels or body weight. Halade *et al* ([@b23-mmr-19-06-4603]) reported that high fat diet-induced hypertriglyceridemia promotes bone marrow adiposity with a lower bone mass. Tatsumi *et al* ([@b24-mmr-19-06-4603]) reported that higher weights have protective effects on bone metabolism in rodents. Obesity reduced bone density in rapidly growing male rats ([@b25-mmr-19-06-4603]). Serum TG levels and body weights were unchanged in the HCD groups compared to those in the controls, indicating that the effects of serum TG levels and weight were excluded in this study. High cholesterol decreased BMD and significantly increased the levels of both bone resorption markers, such as CTX-1 and TRAP, and bone formation markers, such as bone glaprotein (BGP), alkaline phosphatase (ALPL), PINP, indicating that high cholesterol promoted osteoclast-mediated bone resorption and osteoblast-mediated bone formation, resulting in the increased risk of osteoporosis in male rodents. These findings were somewhat inconsistent with those of previous research involving female rodents ([@b26-mmr-19-06-4603]). You *et al* ([@b26-mmr-19-06-4603]) recently reported that HCD administration did not promote bone resorption but inhibited bone formation in female rats. We attribute the above discrepancies mainly to the difference in the genders of the mice used in the two studies. Other authors aimed to study the effects of an HCD on female OP. Since differences in bone metabolism due to differences in endocrine and paracrine factors exist between the sexes ([@b27-mmr-19-06-4603]--[@b29-mmr-19-06-4603]), the effects of hypercholesterolaemia on male and female bone metabolism and the underlying mechanisms may be different. In addition, the authors of one study used an HCD containing 20% lard, which induces obesity and high TG, leading to bone formation inhibition ([@b25-mmr-19-06-4603]). Tintut *et al* ([@b30-mmr-19-06-4603]) recently reported that hypercholesterolaemia promotes osteoclastic differentiation and resorptive activity *in vivo*, consistent with our study. These findings supported our clinical hypothesis. In our animal study, high cholesterol caused trabecular and cortical microstructural damage and reduced bone mechanical strength. Therefore, we believe that high cholesterol damages bone microstructure and decreases bone mechanical strength by excessively enhancing bone transformation, leading to a higher risk of OP and a higher risk of fracture in males. In addition, our findings indicate that the changes observed in the HCD group can be slightly attenuated by withdrawal of the HCD, suggesting that diet modification can ameliorate the negative effects of hypercholesterolaemia on bone.

The ApoE-KO rat is a useful model for studying the functions of congenital hypercholesterolaemia. Rats lacking ApoE have congenital hypercholesterolaemia, as demonstrated by their elevated serum cholesterol levels and unchanged serum TG levels ([@b31-mmr-19-06-4603],[@b32-mmr-19-06-4603]). To the best of our knowledge, this study is the first to investigate the effects of congenital hypercholesterolaemia on male bone. In our ApoE-KO male rat model, ApoE^−/−^ rats displayed an enormous increase in their serum TC levels but no change in their serum TG levels or weights compared to those in control rats. We found that the effects of endogenous hypercholesterolaemia on BMD, bone turnover, bone microstructure and bone strength were similar to those of exogenous hypercholesterolaemia. We regarded endogenous hypercholesterolaemia as a positive-control group. Our animal findings suggest that both endogenous and exogenous hypercholesterolaemia promote the development of male OP by exceedingly promoting both osteoclast activity and osteoblast activity.

As the above results show, high cholesterol can boost both osteoclast and osteoblast functions *in vivo*. To research the direct influence of cholesterol on both osteoclast and osteoblast functions, we designed an *in vitro* cell experiment. Since many cell studies have shown that cholesterol promotes enhanced osteoclast differentiation and osteoclast activity ([@b33-mmr-19-06-4603]) and the conclusion of the effects of cholesterol on osteoblasts is contradictory, we studied only the effects of cholesterol on osteoblast function. We found that free cholesterol increased the expression levels of genes involved in osteoblastic function and that cholesterol can promote osteoblastic function. Li *et al* ([@b34-mmr-19-06-4603]) documented that cholesterol-treated mesenchymal stem cells (MSCs) showed increased expression levels of osteogenic lineage markers, supportive of our conclusion. Liu *et al* ([@b35-mmr-19-06-4603]) reported that the proliferation/viability of primary alveolar osteoblast cells (AOBs) was significantly decreased by simvastatin (a cholesterol-lowering drug) treatment at different concentrations, findings consistent with ours. However, You *et al* ([@b26-mmr-19-06-4603]) reported that free cholesterol inhibits the proliferation and differentiation of osteoblasts *in vitro*, findings inconsistent with ours. We attribute the above difference to the fact that the free cholesterol treatment doses used in that study were different from those used in this study, as our cholesterol treatment doses were lower. In the present study, we observed substantial death in the osteoblast population treated with cholesterol at a concentration higher than 20 µg/ml; thus, we chose a cholesterol treatment dose below 20 µg/ml in subsequent experiments to avoid the toxicity induced by cholesterol levels higher than 20 µg/ml. The authors of the other study used the MC3T3-E1 osteoblast line, and we used rat calvaria primary osteoblasts, which we deemed ideal osteoblast model cells. Thus, our *in vitro* experimental results conform more to those of our *in vivo* animal experiments than to those of the other study. Thus, we believe that our results are more truthful.

The present study had some limitations. In our *in vitro* experiments, we did not investigate the effects of cholesterol on osteoclasts since many studies have found that cholesterol promotes osteoclastic differentiation and function, the results of which were consistent with those of our study. However, additional studies regarding this issue are needed, as are accurate evaluations of cell signal transduction in osteoblasts and cell function and signal transduction in osteoclasts.

In summary, we found that hypercholesterolaemia can promote the development of male OP by excessively promoting both osteoclast activity and osteoblast activity, which excessively enhances the bone transformation rate in men. Both endogenous and exogenous hypercholesterolaemia in two male animal experimental models were used to validate the clinical findings. Again, we found that hypercholesterolaemia damaged the bone microstructure, thus, increasing the risk of osteopenia or OP and reducing bone strength, resulting in a higher risk of fracture. Many *in vitro* studies have shown that cholesterol enhances osteoclast differentiation and osteoclast activity ([@b34-mmr-19-06-4603]). *In vitro*, cholesterol directly upregulated the functions of osteoblasts. Based on these results, the detrimental effects of hypercholesterolaemia on bone health probably represent a higher risk of high-turnover osteoporosis and future fractures in men. In conclusion, we wish to emphasize the importance of preventing and treating hypercholesterolemia to prevent osteoporotic bone loss and of monitoring bone metabolic markers, preferably in conjunction with lowering BMD, in men with hypercholesterolemia for the effective prevention of bone loss and subsequent fractures. In addition, our findings provide a theoretical basis for the development of treatments for high cholesterol-induced osteoporosis.
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![Effects of exogenous hypercholesterolaemia induced by HCD administration on male rats. (A) Serum (a) TC and (b) TG levels, and (c) body weight of the rats. (B) Representative 2D mCT images showing the trabecular and cortical microarchitectures of the femurs of each group. (C) Representative 3D mCT images showing the trabecular microarchitecture of the distal femur and the cortical microarchitecture of the midfemoral diaphyses. (D) The trabecular volumetric BMD (Tb. vBMD) (a) and cortical volumetric BMD (Ct. vBMD) (b) of the femur, as analysed via mCT. (E and F) The bone biomechanical parameters of the femoral diaphysis were calculated from a three-point bending test, and the maximum load (E-a), maximum fracture load (E-b), energy absorption (F-a), stiffness (F-b) and elastic modulus (F-c) of the femoral diaphysis were analysed. (G) The levels of the serum bone resorption markers TRAP (a) and beta-CTX (b) in rats were measured using ELISA kits. (H) The levels of serum bone formation markers BGP (a), ALPL (b) and PINP (c) in rats were measured using ELISA kits. \*P\<0.05 and \*\*P\<0.01 vs. the corresponding NCD group, ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. the corresponding HCD group. HCD, high cholesterol diet; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; BMD, bone mineral density; BGP, bone glaprotein; ALPL, alkaline phosphatase; PINP, type I anterior collagen amino terminal peptide; NCD, normal control diet.](MMR-19-06-4603-g00){#f1-mmr-19-06-4603}

![Effects of endogenous hypercholesterolaemia induced by ApoE knockout on male rats. (A) Serum (a) TC and (b) TG levels, and (c) body weight of the rats. (B) Representative 2D mCT images showing the trabecular and cortical microarchitectures of the femurs of each group. (C) Representative 3D mCT images showing the trabecular microarchitecture of the distal femur and the cortical microarchitecture of the midfemoral diaphyses. (D) Trabecular volumetric BMD (Tb. vBMD) (a) and cortical volumetric BMD (Ct. vBMD) (b) of the femur, as analysed via mCT. (E and F) The bone biomechanical parameters of the femoral diaphysis were calculated using a three-point bending test, and the maximum load (E-a), maximum fracture load (E-b), energy absorption (F-a), stiffness (F-b) and elastic modulus (F-c) of the femoral diaphysis were analysed. (G) The levels of the serum bone resorption markers TRAP (a) and beta-CTX (b) in rats were measured by ELISA kits. (H) The levels of the serum bone formation markers BGP (a), ALPL (b) and PINP (c) in rats were measured by ELISA kits. \*P\<0.05 and \*\*P\<0.01 vs. the corresponding WT group. TC, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; BMD, bone mineral density; BGP, bone glaprotein; ALPL, alkaline phosphatase; PINP, type I anterior collagen amino terminal peptide; WT, wild-type; ApoE^−/−^, ApoE-knockout (KO).](MMR-19-06-4603-g01){#f2-mmr-19-06-4603}

![Effects of cholesterol on primary osteoblast function. (A) We evaluated primary osteoblast H&E staining via microscopy. The cells displayed multiple bumps, via which they appeared to be connected to adjacent cells, as well as large centrally located or shifted cell nuclei (a; ×100 magnification). The cytoplasm appeared violet after alkaline phosphatase (ALP) staining (b; ×400 magnification). The osteoblasts displayed many round or elliptical opaque nodules, which appeared red after Alizarin red staining (c; ×40 magnification) and black after Von Kossa staining, after being cultured for 16 days (d; ×40 magnification). (B) BGP (a), ALPL (b) and collagen I (c) mRNA expression levels were determined by reverse transcription-quantitative polymerase chain reaction. \*P\<0.05, \*\*P\<0.01 vs. control, ^\#^P\<0.05 vs. 10 µg/ml cholesterol. (C) BGP (a), ALPL (b) and collagen I (c) mRNA expression levels after 10 µg/ml cholesterol treatment for 12, 24 and 48 h. \*P\<0.05, \*\*P\<0.01 vs. control. (D) Extracellular BGP (a) and ALPL (b) content was measured by ELISA kits. \*P\<0.05, \*\*P\<0.01 vs. control, ^\#^P\<0.05 vs. 10 µg/ml cholesterol. (E) Extracellular BGP (a) and ALPL (b) content after treatment with 10 µg/ml cholesterol for 12, 24 and 48 h. \*P\<0.05, \*\*P\<0.01 vs. control. BGP, bone glaprotein; ALPL, alkaline phosphatase.](MMR-19-06-4603-g02){#f3-mmr-19-06-4603}

###### 

Clinical characteristics of the subjects with hypercholesterolemia and control subjects.

  Characteristics (mean ± SD)   Controls (n=112)   Hypercholesterolemia (n=104)                                    Total (n=216)
  ----------------------------- ------------------ --------------------------------------------------------------- ---------------
  Age (years)                   48.140±13.750      50.098±13.995                                                   49.065±13.868
  BMI (kg/m^2^)                 25.337±3.810       25.256±3.031                                                    25.299±3.456
  FPG (mmol/l)                  5.421±0.619        5.462±0.469                                                     5.462±0.562
  HbA1 (%)                      5.503±1.139        5.433±0.342                                                     5.454±0.365
  To (ng/ml)                    5.652±1.624        5.669±2.266                                                     5.497±1.972
  FT4 (pmol/l)                  19.256±2.143       18.913±2.704                                                    19.094±2.425
  TSH (µIU/ml)                  2.338±1.691        2.465±1.555                                                     2.398±1.626
  25(OH)D (ng/ml)               28.448±9.183       28.257±10.048                                                   28.358±9.579
  TG (mmol/l)                   1.201±0.328        1.27±0.290                                                      1.234±0.312
  TC (mmol/l)                   4.485±0.496        5.737±0.412^[b](#tfn3-mmr-19-06-4603){ref-type="table-fn"}^     5.076±0.776
  LDL-C (mmol/l                 2.789±0.406        3.722±0.351^[b](#tfn3-mmr-19-06-4603){ref-type="table-fn"}^     3.230±0.602
  HLD-C (mmol/l                 1.175±0.235        1.309±0.262^[b](#tfn3-mmr-19-06-4603){ref-type="table-fn"}^     1.238±0.257
  BMD (g/cm^2^)                 0.536±0.066        0.505±0.092^[b](#tfn3-mmr-19-06-4603){ref-type="table-fn"}^     0.522±0.081
  Beta-CTX (ng/ml)              0.437±0.164        0.5±0.201^[a](#tfn2-mmr-19-06-4603){ref-type="table-fn"}^       0.467±0.185
  PINP (ng/ml)                  46.974±16.259      52.477±19.011^[a](#tfn2-mmr-19-06-4603){ref-type="table-fn"}^   49.572±17.785

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; To, testosterone; FT4, free thyroxine; TSH, thyroid stimulating hormone; 25(OH)D, 25-hydroxyvitamin D; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMD, bone mineral density; beta-CTX, beta collagen cross-linking; PINP, type I anterior collagen amino terminal peptide.

P\<0.05

P\<0.01, significant results.

###### 

Multiple regression analysis between BMD, serum Beta-CTX or PINP and TC, LDL-C, HDL-C.

  Characteristics   BMD                                                      Beta-CTX                                                 PINP
  ----------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Age               −0.389^[b](#tfn6-mmr-19-06-4603){ref-type="table-fn"}^   −0.241^[b](#tfn6-mmr-19-06-4603){ref-type="table-fn"}^   −0.257^[b](#tfn6-mmr-19-06-4603){ref-type="table-fn"}^
  BMI               0.195^[b](#tfn6-mmr-19-06-4603){ref-type="table-fn"}^    −0.051                                                   −0.102
  To                0.153^[a](#tfn5-mmr-19-06-4603){ref-type="table-fn"}^    −0.086                                                   0.017
  TG                −0.024                                                   0.049                                                    0.123
  TC                −0.175^[b](#tfn6-mmr-19-06-4603){ref-type="table-fn"}^   0.169^[a](#tfn5-mmr-19-06-4603){ref-type="table-fn"}^    0.166^[a](#tfn5-mmr-19-06-4603){ref-type="table-fn"}^
  LDL-C             −0.073                                                   0.172^[a](#tfn5-mmr-19-06-4603){ref-type="table-fn"}^    −0.068
  HLD-C             0.073                                                    −0.038                                                   −0.021

BMD, bone mineral density; beta-CTX, beta collagen cross-linking; PINP, type I anterior collagen amino terminal peptide; BMI, body mass index; To, testosterone; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

P\<0.05

P\<0.01, significant results.

###### 

Micro-CT measurements in male rats.

  Parameters (abbreviations)                   NCD            HCD                                                            HCD+NCD                                                                                                        WT              ApoE^−/−^
  -------------------------------------------- -------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------- ----------------------------------------------------------------
  Trebecular parameter                                                                                                                                                                                                                                      
    Percent bone volume (%) (BV/TV)            32.615±7.401   18.01±3.901^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^    25.614±2.834^[a](#tfn8-mmr-19-06-4603){ref-type="table-fn"},[d](#tfn11-mmr-19-06-4603){ref-type="table-fn"}^   42.858±5.627    33.137±4.434^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Bone surface density (1/mm) (BS/TV)        8.533±1.592    5.687±1.138^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^    6.05±0.907^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^                                                     12.359±0.941    10.329±0.711^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Trabecular thickness (mm) (Tb.Th)          0.142±0.01     0.131±0.008^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^    0.131±0.003^[a](#tfn8-mmr-19-06-4603){ref-type="table-fn"}^                                                    0.125±0.006     0.112±0.004^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Trabecular number (1/mm) (Tb.N)            2.398±0.492    1.45±0.373^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^     1.743±0.248^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^                                                    3.461±0.334     2.916±0.332^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Connectivity density (1/mm^3^) (Conn.Dn)   57.15±15.627   24.165±6.569^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^   28.796±8.819^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^                                                   94.164±8.384    110.377±17.264^[a](#tfn8-mmr-19-06-4603){ref-type="table-fn"}^
    Trabecular separation (mm) (Tb.Sp)         0.307±0.067    0.542±0.116^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^    0.452±0.105^[c](#tfn10-mmr-19-06-4603){ref-type="table-fn"}^                                                   0.210±0.028     0.278±0.051^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Trabecular pattern factor (1/mm) (Tb.Pf)   2.66±1.841     7.721±2.206^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^    5.94±2.038^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^                                                     −0.837±2.334    1.754±1.772^[a](#tfn8-mmr-19-06-4603){ref-type="table-fn"}^
    Structure model index (SMI)                1.105±0.25     1.782±0.336^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^    1.526±0.278^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^                                                    0.812±0.246     1.267±0.176^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
  Cortical parameter                                                                                                                                                                                                                                        
    Percent bone volume (%) (BV/TV)            92.361±0.284   91.618±0.277^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^   91.888±0.282                                                                                                   89.193±0.255    88.494±0.29^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Bone surface density (1/mm) (BS/TV)        6.300±0.68     5.871±0.077^[a](#tfn8-mmr-19-06-4603){ref-type="table-fn"}^    5.967±0.126                                                                                                    7.218±0.086     6.999±0.134^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Cortical thickness (mm) (Ct.Th)            0.522±0.01     0.487±0.06^[a](#tfn8-mmr-19-06-4603){ref-type="table-fn"}^     0.518±0.001^[c](#tfn10-mmr-19-06-4603){ref-type="table-fn"}^                                                   0.501±0.007     0.487±0.008^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^
    Cortical area (mm^2^) (Ct.Ar)              32.409±2.204   29.136±1.759^[b](#tfn9-mmr-19-06-4603){ref-type="table-fn"}^   31.623±2.325^[c](#tfn10-mmr-19-06-4603){ref-type="table-fn"}^                                                  23.074±1.3890   24.392±2.358

NCD, normal control diet; HCD, high cholesterol diet; WT, wild-type; ApoE^−/−^, apolipoprotein E knockout.

P\<0.01

P\<0.01 vs. NCD

P\<0.05

P\<0.01 vs. the corresponding HCD.
